This session will provide veterinarians with a comprehensive overview of global scientific and medical data for Librela (bedinvetmab), drawing on over three years of real-world clinical experience. Attendees will gain insights into pharmacovigilance, safety profiles, and adverse event reporting from millions of doses administered worldwide. The presentation will discuss strengths and limitations of post-marketing data, highlight the most commonly reported adverse events, and address specific safety concerns—including joint health and neurological events. Practical recommendations for clinical use and monitoring will be shared, empowering veterinarians to make informed decisions and optimize outcomes for dogs with osteoarthritis.
